Ping Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ping Hu has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Jianlin Shi
Shanghai Institute of Ceramics, Chinese Academy of Sciences
16 shared publications Yuedong Guo
State Key Laboratory of High Performance Ceramics, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Chinese Academy of Medical Sciences, Shanghai, 200050, PR China
6 shared publicationsHan Jiang
Shanghai Institute of Ceramics, Chinese Academy of Sciences; Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease, Chinese Academy of Medical Sciences, Shanghai 200050, China
4 shared publicationsQunqun Bao
Shanghai Frontiers Science Center of Nanocatalytic Medicine, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China
4 shared publicationsWenming Fang
Shanghai Institute of Ceramics Chinese Academy of Sciences Research Unit of Nano catalytic Medicine in Specific Therapy for Serious Disease Chinese Academy of Medical Sciences Shanghai 200050 P. R. China
4 shared publicationsZhiguo Yu
State Key Laboratory of Silicon and Advanced Semiconductor Materials and School of Materials Science and Engineering Zhejiang University Hangzhou 310027 P. R. China
4 shared publications
Latest Publications
- 5 November 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (45) , 31123-31136
Disassembly of Extracellular Matrix and Intercellular Adhesion Enables Noninvasive Bladder Cancer Disaggregation
Bladder cancer is a type of prevalent malignant tumor of the urinary system, for which transurethral endoscopic resection serves as the first-line clinical treatment, followed by adjuvant intravesical chemotherapy or BCG immunotherapy. Current clinical regimens suffer largely from surgical trauma, procedural risks, long treatment cycles, severe systemic side effects, and high recurrence rates; conventional tumor cell-killing modalities relying on highly toxic chemotherapeutics and vaccines will inevitably damage normal tissues and induce less-tolerable adverse reactions in patients. By overturning this conventional therapeutic philosophy, we previously proposed a globally pioneering bladder cancer disaggregation therapy: calcium chelation disrupts intercellular cadherin-mediated adhesion, triggering exfoliation and detachment of tumor cells, which are subsequently excreted from the body via urine. Taking advantage of the unique anatomical and physiological characteristics of the bladder, this strategy achieves noninvasive tumor elimination through spontaneous urinary expulsion. To further enhance the disaggregation efficiency, the present work advances this concept by incorporating collagenase to realize the dual disruption of both cadherin and collagen proteins. To this end, we constructed a layered double hydroxide (LDH) nanoplatform coloaded with collagenase and EDTA. The nanosystem efficiently degrades key extracellular matrix components, thereby relieving steric hindrance and exposing cellular surfaces, which significantly promotes the subsequent disruption of intercellular junctions via enhanced EDTA accessibility for calcium deprivation from E-cadherin. This work establishes an efficient, noncell-killing modality for the physical clearance of bladder tumors, offering a promising alternative clinical strategy to suppress tumor recurrence and reduce systemic toxic side effects.
- 5 November 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (45) , 31123-31136
Disassembly of Extracellular Matrix and Intercellular Adhesion Enables Noninvasive Bladder Cancer Disaggregation
Bladder cancer is a type of prevalent malignant tumor of the urinary system, for which transurethral endoscopic resection serves as the first-line clinical treatment, followed by adjuvant intravesical chemotherapy or BCG immunotherapy. Current clinical regimens suffer largely from surgical trauma, procedural risks, long treatment cycles, severe systemic side effects, and high recurrence rates; conventional tumor cell-killing modalities relying on highly toxic chemotherapeutics and vaccines will inevitably damage normal tissues and induce less-tolerable adverse reactions in patients. By overturning this conventional therapeutic philosophy, we previously proposed a globally pioneering bladder cancer disaggregation therapy: calcium chelation disrupts intercellular cadherin-mediated adhesion, triggering exfoliation and detachment of tumor cells, which are subsequently excreted from the body via urine. Taking advantage of the unique anatomical and physiological characteristics of the bladder, this strategy achieves noninvasive tumor elimination through spontaneous urinary expulsion. To further enhance the disaggregation efficiency, the present work advances this concept by incorporating collagenase to realize the dual disruption of both cadherin and collagen proteins. To this end, we constructed a layered double hydroxide (LDH) nanoplatform coloaded with collagenase and EDTA. The nanosystem efficiently degrades key extracellular matrix components, thereby relieving steric hindrance and exposing cellular surfaces, which significantly promotes the subsequent disruption of intercellular junctions via enhanced EDTA accessibility for calcium deprivation from E-cadherin. This work establishes an efficient, noncell-killing modality for the physical clearance of bladder tumors, offering a promising alternative clinical strategy to suppress tumor recurrence and reduce systemic toxic side effects.
- 17 February 2026
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (4) , 1021-1035
Estrogen Axis-Targeted Nanocatalytic Synergetic Therapy against Refractory Ovarian Cancer
- 17 February 2026
- Published by American Chemical Society (ACS) in ACS Nano Medicine
- Vol. 1 (4) , 1021-1035
Estrogen Axis-Targeted Nanocatalytic Synergetic Therapy against Refractory Ovarian Cancer
- 28 January 2026
- Published by Elsevier in Biomaterials
- Vol. 330, 124029
Tumor disaggregation sensitizes radio-therapy for low rectal tumor
- 28 January 2026
- Published by Elsevier in Biomaterials
- Vol. 330, 124029
Tumor disaggregation sensitizes radio-therapy for low rectal tumor
- 13 November 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (44) , 25516-25525
Calcium ion nanomodulators induce pyroptosis for tumor immunotherapy
A pH-responsive nanomodulator constructed from calcium–aluminum layered double hydroxide and curcumin (CUR, a calcium pump inhibitor) induces mitochondrial calcium overload-mediated pyroptosis, thereby activating anti-tumor immune responses.
- 13 November 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (44) , 25516-25525
Calcium ion nanomodulators induce pyroptosis for tumor immunotherapy
A pH-responsive nanomodulator constructed from calcium–aluminum layered double hydroxide and curcumin (CUR, a calcium pump inhibitor) induces mitochondrial calcium overload-mediated pyroptosis, thereby activating anti-tumor immune responses.
- Open Access
- 18 August 2025
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 16 (1) , 1-19
Disaggregation of luminal alimentary tract tumors by E-cad disruption: a report of six cases
Background: Malignant luminal alimentary tract tumor chemotherapy remains a great challenge at present due to risks and toxicities associated with current chemodrugs, as well as the potential for treatment resistance. Layered double hydroxide (LDH)/ethylenediamine tetraacetic acid (EDTA), such a tumor disaggregation-based treatment reagent for alimentary tract cancers was assessed in six patients bearing luminal tumors. The aim of this study was to evaluate the bio-safety and efficacy of LDH/EDTA for treating luminal alimentary tract tumors with high malignance. Methods: Two patients with colorectal cancer received intestinal perfusion of LDH/EDTA by colonoscopy every week for 6 weeks, and four patients with esophagus tumors received oral administration of LDH/EDTA for at least 1 month. The efficacy of LDH/EDTA were evaluated by determining tumor size reductions through contrast-enhanced CT imaging. Tumor cell dissociation was evaluated by flow cytometry to validate the tumor disaggregation. Results: The colorectal cancer patients presented 33.3% and 16.7% reductions in tumor size after LDH/EDTA treatment. Additionally, symptoms of intestinal obstruction were largely alleviated. Four esophagus cancer patients experienced 6.7%, 26.7%, 16.7% and 15.4% reductions in tumor size, respectively, and symptoms of dysphagia were largely alleviated. All enrolled patients had normal physical condition based on blood routine examinations and hepatic and renal function examinations. Conclusions: Tumor disaggregation strategy for luminal alimentary tract tumor removal is a highly promising, mild, noninvasive modality, which offers an unprecedented paradigm for highly effective and safe treatment for patients with luminal alimentary tract tumors. This study is registered with www.chictr.org.cn (ChiCTR2200061587, ChiCTR2200065010).
- 18 August 2025
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 16 (1) , 1-19
Open AccessDisaggregation of luminal alimentary tract tumors by E-cad disruption: a report of six cases
Background: Malignant luminal alimentary tract tumor chemotherapy remains a great challenge at present due to risks and toxicities associated with current chemodrugs, as well as the potential for treatment resistance. Layered double hydroxide (LDH)/ethylenediamine tetraacetic acid (EDTA), such a tumor disaggregation-based treatment reagent for alimentary tract cancers was assessed in six patients bearing luminal tumors. The aim of this study was to evaluate the bio-safety and efficacy of LDH/EDTA for treating luminal alimentary tract tumors with high malignance. Methods: Two patients with colorectal cancer received intestinal perfusion of LDH/EDTA by colonoscopy every week for 6 weeks, and four patients with esophagus tumors received oral administration of LDH/EDTA for at least 1 month. The efficacy of LDH/EDTA were evaluated by determining tumor size reductions through contrast-enhanced CT imaging. Tumor cell dissociation was evaluated by flow cytometry to validate the tumor disaggregation. Results: The colorectal cancer patients presented 33.3% and 16.7% reductions in tumor size after LDH/EDTA treatment. Additionally, symptoms of intestinal obstruction were largely alleviated. Four esophagus cancer patients experienced 6.7%, 26.7%, 16.7% and 15.4% reductions in tumor size, respectively, and symptoms of dysphagia were largely alleviated. All enrolled patients had normal physical condition based on blood routine examinations and hepatic and renal function examinations. Conclusions: Tumor disaggregation strategy for luminal alimentary tract tumor removal is a highly promising, mild, noninvasive modality, which offers an unprecedented paradigm for highly effective and safe treatment for patients with luminal alimentary tract tumors. This study is registered with www.chictr.org.cn (ChiCTR2200061587, ChiCTR2200065010).
- 21 February 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 35 (27)
Inhibitory Microenvironment Remodeling Enhances STING Activation for Solid Tumor Immunotherapy
The immunomodulatory effect of the interferon gene‐stimulating factor (STING) pathway makes it an important target for tumor immunotherapy, which, however, suffers from the easy degradation and deteriorated stimulatory capacity of current STING agonists in the solid tumor microenvironment. Herein, a nanocomposite medicine, MLAP, is constructed by intercalating STING agonist ADU‐S100 into Mn‐doped layered double hydroxide, which is capable of modulating the immune microenvironment of solid tumors to enhance STING activation. Importantly, the intercalation in the interlayer structure enhances the intracellular permeability of STING agonists, meanwhile, the activation of the STING pathway by ADU‐S100 is amplified by the sensitizing effect of Mn2+. In addition, the moderate alkalinity of MLAP neutralizes the acidity of the tumor microenvironment and catalyzes the decomposition of hydrogen peroxide to produce oxygen, rectifying the acidic and hypoxia immunosuppressive microenvironment and thus strengthening the immune activation efficacy of STING agonists. This work provides an excellent carrier for STING agonists, which not only improves the bioavailability of STING agonists but also remodels the immune microenvironment for boosted solid tumor immunotherapy.
- 21 February 2025
- Published by Wiley in Advanced Functional Materials
- Vol. 35 (27)
Inhibitory Microenvironment Remodeling Enhances STING Activation for Solid Tumor Immunotherapy
The immunomodulatory effect of the interferon gene‐stimulating factor (STING) pathway makes it an important target for tumor immunotherapy, which, however, suffers from the easy degradation and deteriorated stimulatory capacity of current STING agonists in the solid tumor microenvironment. Herein, a nanocomposite medicine, MLAP, is constructed by intercalating STING agonist ADU‐S100 into Mn‐doped layered double hydroxide, which is capable of modulating the immune microenvironment of solid tumors to enhance STING activation. Importantly, the intercalation in the interlayer structure enhances the intracellular permeability of STING agonists, meanwhile, the activation of the STING pathway by ADU‐S100 is amplified by the sensitizing effect of Mn2+. In addition, the moderate alkalinity of MLAP neutralizes the acidity of the tumor microenvironment and catalyzes the decomposition of hydrogen peroxide to produce oxygen, rectifying the acidic and hypoxia immunosuppressive microenvironment and thus strengthening the immune activation efficacy of STING agonists. This work provides an excellent carrier for STING agonists, which not only improves the bioavailability of STING agonists but also remodels the immune microenvironment for boosted solid tumor immunotherapy.
- Open Access
- 30 July 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-11
Magnetothermal-activated gene editing strategy for enhanced tumor cell apoptosis
Precise and effective initiation of the apoptotic mechanism in tumor cells is one of the most promising approaches for the treatment of solid tumors. However, current techniques such as high-temperature ablation or gene editing suffer from the risk of damage to adjacent normal tissues. This study proposes a magnetothermal-induced CRISPR-Cas9 gene editing system for the targeted knockout of HSP70 and BCL2 genes, thereby enhancing tumor cell apoptosis. The magnetothermal nanoparticulate platform is composed of superparamagnetic ZnCoFe2O4@ZnMnFe2O4 nanoparticles and the modified polyethyleneimine (PEI) and hyaluronic acid (HA) on the surface, on which plasmid DNA can be effectively loaded. Under the induction of a controllable alternating magnetic field, the mild magnetothermal effect (42℃) not only triggers dual-genome editing to disrupt the apoptosis resistance mechanism of tumor cells but also sensitizes tumor cells to apoptosis through the heat effect itself, achieving a synergistic therapeutic effect. This strategy can precisely regulate the activation of the CRISPR-Cas9 system for tumor cell apoptosis without inducing significant damage to healthy tissues, thus providing a new avenue for cancer treatment.
- 30 July 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-11
Open AccessMagnetothermal-activated gene editing strategy for enhanced tumor cell apoptosis
Precise and effective initiation of the apoptotic mechanism in tumor cells is one of the most promising approaches for the treatment of solid tumors. However, current techniques such as high-temperature ablation or gene editing suffer from the risk of damage to adjacent normal tissues. This study proposes a magnetothermal-induced CRISPR-Cas9 gene editing system for the targeted knockout of HSP70 and BCL2 genes, thereby enhancing tumor cell apoptosis. The magnetothermal nanoparticulate platform is composed of superparamagnetic ZnCoFe2O4@ZnMnFe2O4 nanoparticles and the modified polyethyleneimine (PEI) and hyaluronic acid (HA) on the surface, on which plasmid DNA can be effectively loaded. Under the induction of a controllable alternating magnetic field, the mild magnetothermal effect (42℃) not only triggers dual-genome editing to disrupt the apoptosis resistance mechanism of tumor cells but also sensitizes tumor cells to apoptosis through the heat effect itself, achieving a synergistic therapeutic effect. This strategy can precisely regulate the activation of the CRISPR-Cas9 system for tumor cell apoptosis without inducing significant damage to healthy tissues, thus providing a new avenue for cancer treatment.
- 17 May 2024
- Published by Wiley in Advanced Functional Materials
- Vol. 34 (44)
Fe/Al‐LDH Nanomedicine for Antitumor Ferroptosis‐Immunotherapy by Immunosuppression Reversal
Ferroptosis is recognized as a novel type of programmed cell death with efficient immunogenicity to activate T cell‐mediated adaptive immune responses. However, conventional ferroptosis‐inducers mostly show poor efficacies due to their less effectiveness in immune regulation. In addition, suppression of T cells by M2‐type macrophages within the tumor microenvironment further weaken the immunotherapeutic effect of ferroptosis. To overcome these challenges, herein, an extremely simple Fe/Al‐layered double hydroxide (Fe/Al‐LDH) nanomedicine of enhanced iron concentration is reported, which is capable of selective degradation in acidic microenvironments to induce tumor cell ferroptosis and in the meantime reversing the immunosuppressive microenvironment by utilizing tumor cell ferroptosis and macrophage M1 polarization to synergistically enhance T cell immune response. This combined strategy has achieved excellent therapeutic efficacy in an orthotopic bilateral breast cancer model, demonstrating the great application potential of Fe/Al‐layered double hydroxide nanoplatform for iron ions‐regulated cancer immunotherapy.
- 17 May 2024
- Published by Wiley in Advanced Functional Materials
- Vol. 34 (44)
Fe/Al‐LDH Nanomedicine for Antitumor Ferroptosis‐Immunotherapy by Immunosuppression Reversal
Ferroptosis is recognized as a novel type of programmed cell death with efficient immunogenicity to activate T cell‐mediated adaptive immune responses. However, conventional ferroptosis‐inducers mostly show poor efficacies due to their less effectiveness in immune regulation. In addition, suppression of T cells by M2‐type macrophages within the tumor microenvironment further weaken the immunotherapeutic effect of ferroptosis. To overcome these challenges, herein, an extremely simple Fe/Al‐layered double hydroxide (Fe/Al‐LDH) nanomedicine of enhanced iron concentration is reported, which is capable of selective degradation in acidic microenvironments to induce tumor cell ferroptosis and in the meantime reversing the immunosuppressive microenvironment by utilizing tumor cell ferroptosis and macrophage M1 polarization to synergistically enhance T cell immune response. This combined strategy has achieved excellent therapeutic efficacy in an orthotopic bilateral breast cancer model, demonstrating the great application potential of Fe/Al‐layered double hydroxide nanoplatform for iron ions‐regulated cancer immunotherapy.
- Open Access
- 8 December 2023
- Published by Wiley in Advanced Science
- Vol. 11 (6) , e2307094
Anti‐Acidification and Immune Regulation by Nano‐Ceria‐Loaded Mg–Al Layered Double Hydroxide for Rheumatoid Arthritis Therapy
Rheumatoid arthritis (RA) is a chronic autoimmune disease featuring an abnormal immune microenvironment and resultant accumulation of hydrogen ions (H+) produced by activated osteoclasts (OCs). Currently, clinic RA therapy can hardly achieve sustained or efficient therapeutic outcomes due to the failures in generating sufficient immune modulation and manipulating the accumulation of H+ that deteriorates bone damage. Herein, a highly effective immune modulatory nanocatalytic platform, nanoceria‐loaded magnesium aluminum layered double hydroxide (LDH‐CeO2), is proposed for enhanced immune modulation based on acid neutralization and metal ion inherent bioactivity. Specifically, the mild alkaline LDH initiates significant M2 repolarization of macrophages triggered by the elevated antioxidation effect of CeO2 via neutralizing excessive H+ in RA microenvironment, thus resulting in the efficient recruitment of regulatory T cell (Treg) and suppressions on T helper 17 cell (Th 17) and plasma cells. Moreover, the osteogenic activity is stimulated by the Mg ion released from LDH, thereby promoting the damaged bone healing. The encouraging therapeutic outcomes in adjuvant‐induced RA model mice demonstrate the high feasibility of such a therapeutic concept, which provides a novel and efficient RA therapeutic modality by the immune modulatory and bone‐repairing effects of inorganic nanocatalytic material.
- 8 December 2023
- Published by Wiley in Advanced Science
- Vol. 11 (6) , e2307094
Open AccessAnti‐Acidification and Immune Regulation by Nano‐Ceria‐Loaded Mg–Al Layered Double Hydroxide for Rheumatoid Arthritis Therapy
Rheumatoid arthritis (RA) is a chronic autoimmune disease featuring an abnormal immune microenvironment and resultant accumulation of hydrogen ions (H+) produced by activated osteoclasts (OCs). Currently, clinic RA therapy can hardly achieve sustained or efficient therapeutic outcomes due to the failures in generating sufficient immune modulation and manipulating the accumulation of H+ that deteriorates bone damage. Herein, a highly effective immune modulatory nanocatalytic platform, nanoceria‐loaded magnesium aluminum layered double hydroxide (LDH‐CeO2), is proposed for enhanced immune modulation based on acid neutralization and metal ion inherent bioactivity. Specifically, the mild alkaline LDH initiates significant M2 repolarization of macrophages triggered by the elevated antioxidation effect of CeO2 via neutralizing excessive H+ in RA microenvironment, thus resulting in the efficient recruitment of regulatory T cell (Treg) and suppressions on T helper 17 cell (Th 17) and plasma cells. Moreover, the osteogenic activity is stimulated by the Mg ion released from LDH, thereby promoting the damaged bone healing. The encouraging therapeutic outcomes in adjuvant‐induced RA model mice demonstrate the high feasibility of such a therapeutic concept, which provides a novel and efficient RA therapeutic modality by the immune modulatory and bone‐repairing effects of inorganic nanocatalytic material.
- Open Access
- 11 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-20
Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy
Pro-tumoral macrophages in lung tumors present a significant challenge in immunotherapy. Here, we introduce a pH-responsive nanomedicine approach for activating anti-tumoral macrophages and dendritic cells. Using a layered double hydroxide nanosheet carrier, we co-deliver a T-type calcium channel inhibitor (TTA-Q6) and a CD47 inhibitor (RRX-001) into lung tumors. In the tumor acidic environment, TTA-Q6 is released, disrupting cancer cell calcium uptake, causing endoplasmic reticulum stress and inducing calreticulin transfer to the cell surface. Surface calreticulin activates macrophages and triggers dendritic cell maturation, promoting effective antigen presentation and therefore activating antitumor T cells. Simultaneously, RRX-001 reduces CD47 protein levels, aiding in preventing immune escape by calreticulin-rich cancer cells. In lung tumor models in male mice, this combined approach shows anti-tumor effects and immunity against tumor re-exposure, highlighting its potential for lung cancer immunotherapy.
- 11 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-20
Open AccessNanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy
Pro-tumoral macrophages in lung tumors present a significant challenge in immunotherapy. Here, we introduce a pH-responsive nanomedicine approach for activating anti-tumoral macrophages and dendritic cells. Using a layered double hydroxide nanosheet carrier, we co-deliver a T-type calcium channel inhibitor (TTA-Q6) and a CD47 inhibitor (RRX-001) into lung tumors. In the tumor acidic environment, TTA-Q6 is released, disrupting cancer cell calcium uptake, causing endoplasmic reticulum stress and inducing calreticulin transfer to the cell surface. Surface calreticulin activates macrophages and triggers dendritic cell maturation, promoting effective antigen presentation and therefore activating antitumor T cells. Simultaneously, RRX-001 reduces CD47 protein levels, aiding in preventing immune escape by calreticulin-rich cancer cells. In lung tumor models in male mice, this combined approach shows anti-tumor effects and immunity against tumor re-exposure, highlighting its potential for lung cancer immunotherapy.